Search From Over Half a Million Titles


Pharmaceuticals and Healthcare » Pharmaceuticals » Oncology

Myelodysplastic Syndrome - Market Insights, Epidemiology and Market Forecast – 2025

  • ID:RM0034220
  • Published: September-2017
  • Pages:70
  • DelveInsight
1 of 3

DelveInsight s Myelodysplastic Syndrome - Market Insights, Epidemiology and Market Forecast - Market Insights, Epidemiology and Market Forecast 2025 report provides an overview of the disease and in depth research related to Myelodysplastic Syndrome - Market Insights, Epidemiology and Market Forecast for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025.

This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Myelodysplastic Syndrome - Market Insights, Epidemiology and Market Forecast. It enables understanding of the historical and forecasted epidemiological data for the diagnosed prevalent cases of Myelodysplastic Syndrome - Ma........
Show More
1 of 3


1. Report Introduction
2. Myelodysplastic Syndrome Market Overview at a Glance
2.1. Total Market Share Distribution of Myelodysplastic Syndrome for 7 MM in 2016
2.2. Total Market Share Distribution of Myelodysplastic Syndrome for 7 MM in 2025
3. Myelodysplastic Syndrome
3.1.1. Overview
3.1.2. Symptoms
3.1.3. Pathophysiology
3.1.4. Staging
3.1.5. Diagnosis
3.1.6. Treatment
4. Epidemiology and Patient Population
4.1.1. United States
4.1.1.1. Diagnosed Cases of Myelodysplastic Syndrome in United States
4.1.2. Germany
4.1.2.1. Diagnosed Cases of Myelodysplastic Syndrome in Germany
4.1.3. France
4.1.3.1. Diagnosed Cases of Myelodysplastic Syndrome in France
4.1.4. Italy
4.1.4.1. Diagnosed Cases of Myelodysplastic Syndrome in Italy
4.1.5. Spain
4.1.5.1. Diagnosed Cases of Myelodysplastic Syndrome in Spain
4.1.6. United Kingdom
4.1.6.1. Diagnosed Cases of Myelodysplastic Syndrome in United Kingdom
5. Treatment Algorithm
5.1.1. Treatment Guidelines/Practices
6. Marketed Drugs for Myelodysplastic Syndrome
6.1. Drug 1: Company A
6.1.1. Drug Description
6.1.2. Mechanism of Action
6.1.3. Regulatory Milestones
6.1.4. Advantages & Disadvantages
6.1.5. Safety and Efficacy
6.1.6. Product Profile
6.1.7. Patent Status
6.2. Drug 2: Company B
6.2.1. Drug Description
6.2.2. Mechanism of Action
6.2.3. Regulatory Milestones
6.2.4. Advantages & Disadvantages
6.2.5. Safety and Efficacy
6.2.6. Product Profile
6.2.7. Patent Status
7. Emerging Therapies
7.1. Drug 3: Company C
7.1.1. Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Product Profile
7.1.5. Launch Date
7.1.6. Clinical Development
7.1.7. Clinical Pipeline Activity
7.1.8. Ongoing Trials Information
7.1.9. Clinical Trial by Phase
7.2. Drug 4: Company B
7.2.1. Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Product Profile
7.2.5. Launch Date
7.2.6. Clinical Development
7.2.7. Clinical Pipeline Activity
7.2.8. Ongoing Trials Information
7.2.9. Clinical Trial by Phase
8. Overview of Total Myelodysplastic Syndrome Market (2016 & 2025)
9. Myelodysplastic Syndrome: Country-Wise Market Analysis
9.1. United States
9.1.1. Historical Market Size (2015-2016)
9.1.2. Forecasted Market Size (2017-2025)
9.2. Germany Market Size
9.2.1. Historical Market Size (2015-2016)
9.2.2. Forecasted Market Size (2017-2025)
9.3. France Market Size
9.3.1. Historical Market Size (2015-2016)
9.3.2. Forecasted Market Size (2017-2025)
9.4. United Kingdom Market Size
9.4.1. Historical Market Size (2015-2016)
9.4.2. Forecasted Market Size (2017-2025)
9.5. Spain Market Size
9.5.1. Historical Market Size (2015-2016)
9.5.2. Forecasted Market Size (2017-2025)
9.6. Italy Market Size
9.6.1. Historical Market Size (2015-2016)
9.6.2. Forecasted Market Size (2017-2025)
9.7. Japan Market Size
9.7.1. Historical Market Size (2015-2016)
9.7.2. Forecasted Market Size (2017-2025)
10. Market Drivers
11. Market Restraints
12. Appendix
13. Report Methodology
14. Consulting Services
15. Disclaimer
16. About DelveInsight


List of Tables

Table 1: Diagnosed Cases Myelodysplastic Syndrome in United States (2015-2025)
Table 2: Diagnosed Cases Myelodysplastic Syndrome in Germany (2015-2025)
Table 3: Diagnosed Cases Myelodysplastic Syndrome in France (2015-2025)
Table 4: Diagnosed Cases Myelodysplastic Syndrome in United Kingdom (2015-2025)
Table 5: Diagnosed Cases Myelodysplastic Syndrome in Spain (2015-2025)
Table 6: Diagnosed Cases Myelodysplastic Syndrome in Italy (2015-2025)
Table 7: Diagnosed Cases Myelodysplastic Syndrome in Japan (2015-2025)
Table 8: List of Marketed Drugs for Myelodysplastic Syndrome
Table 9: List of Pipeline Phase III Drugs for Myelodysplastic Syndrome
Table 10: Drug 1, Clinical Trials by Zone, 2017
Table 11: Clinical Trials by Trial status, 2017
Table 12: Drug 2, Clinical Trials by Zone, 2017
Table 13: Clinical Trials by Trial status, 2017
Table 14: Drug 3, Clinical Trials by Zone, 2017
Table 15: Clinical Trials by Trial status, 2017
Table 16: United States Market Size of Myelodysplastic Syndrome in USD, Million (2015-2025)
Table 17: Germany Market Size of Myelodysplastic Syndrome in USD, Million (2015-2025)
Table 18: France Market Size of Myelodysplastic Syndrome in USD, Million (2015-2025)
Table 19: United Kingdom Market Size of Myelodysplastic Syndrome in USD, Million (2015-2025)
Table 20: Spain Market Size of Myelodysplastic Syndrome in USD, Million (2015-2025)
Table 21: Italy Market Size of Myelodysplastic Syndrome in USD, Million (2015-2025)
Table 22: Japan Market Size of Myelodysplastic Syndrome in USD, Million (2015-2025)

List of Figures
Figure 1: Diagnosed Cases Myelodysplastic Syndrome in United States (2015-2025)
Figure 2: Diagnosed Cases Myelodysplastic Syndrome in Germany (2015-2025)
Figure 3: Diagnosed Cases Myelodysplastic Syndrome in France (2015-2025)
Figure 4: Diagnosed Cases Myelodysplastic Syndrome in United Kingdom (2015-2025)
Figure 5: Diagnosed Cases Myelodysplastic Syndrome in Spain (2015-2025)
Figure 6: Diagnosed Cases Myelodysplastic Syndrome in Italy (2015-2025)
Figure 7: Diagnosed Cases Myelodysplastic Syndrome in Japan (2015-2025)
Figure 8: List of Marketed Drugs for Myelodysplastic Syndrome
Figure 9: List of Pipeline Phase III Drugs for Myelodysplastic Syndrome
Figure 10: Drug 1, Clinical Trials by Zone (%), 2017
Figure 11: Clinical Trials by Trial status, 2017
Figure 12: Drug 2, Clinical Trials by Zone (%), 2017
Figure 13: Clinical Trials by Trial status, 2017
Figure 14: Drug 3, Clinical Trials by Zone (%), 2017
Figure 15: Clinical Trials by Trial status, 2017
Figure 16: United States Market Size of Myelodysplastic Syndrome in USD, Million (2015-2025)
Figure 17: Germany Market Size of Myelodysplastic Syndrome in USD, Million (2015-2025)
Figure 18: France Market Size of Myelodysplastic Syndrome in USD, Million (2015-2025)
Figure 19: United Kingdom Market Size of Myelodysplastic Syndrome in USD, Million (2015-2025)
Figure 20: Spain Market Size of Myelodysplastic Syndrome in USD, Million (2015-2025)
Figure 21: Italy Market Size of Myelodysplastic Syndrome in USD, Million (2015-2025)
Figure 22: Japan Market Size of Myelodysplastic Syndrome in USD, Million (2015-2025)
Myelodysplastic Syndrome Market (7MM)
Myelodysplastic Syndrome Market forecasting
Myelodysplastic Syndrome Sales forecasting
Myelodysplastic Syndrome Market segments
Myelodysplastic Syndrome Epidemiology
Myelodysplastic Syndrome Pipeline products and technologies
Myelodysplastic Syndrome Competitive landscape
Myelodysplastic Syndrome SWOT analysis
Myelodysplastic Syndrome Market Driver s and barriers
Myelodysplastic Syndrome Key Companies and Funding


List Of Tables

Table 1: Diagnosed Cases Myelodysplastic Syndrome in United States (2015-2025)
Table 2: Diagnosed Cases Myelodysplastic Syndrome in Germany (2015-2025)
Table 3: Diagnosed Cases Myelodysplastic Syndrome in France (2015-2025)
Table 4: Diagnosed Cases Myelodysplastic Syndrome in United Kingdom (2015-2025)
Table 5: Diagnosed Cases Myelodysplastic Syndrome in Spain (2015-2025)
Table 6: Diagnosed Cases Myelodysplastic Syndrome in Italy (2015-2025)
Table 7: Diagnosed Cases Myelodysplastic Syndrome in Japan (2015-2025)
Table 8: List of Marketed Drugs for Myelodysplastic Syndrome
Table 9: List of Pipeline Phase III Drugs for Myelodysplastic Syndrome
Table 10: Drug 1, Clinical Trials by Zone, 2017
Table 11: Clinical Trials by Trial status, 2017
Table 12: Drug 2, Clinical Trials by Zone, 2017
Table 13: Clinical Trials by Trial status, 2017
Table 14: Drug 3, Clinical Trials by Zone, 2017
Table 15: Clinical Trials by Trial status, 2017
Table 16: United States Market Size of Myelodysplastic Syndrome in USD, Million (2015-2025)
Table 17: Germany Market Size of Myelodysplastic Syndrome in USD, Million (2015-2025)
Table 18: France Market Size of Myelodysplastic Syndrome in USD, Million (2015-2025)
Table 19: United Kingdom Market Size of Myelodysplastic Syndrome in USD, Million (2015-2025)
Table 20: Spain Market Size of Myelodysplastic Syndrome in USD, Million (2015-2025)
Table 21: Italy Market Size of Myelodysplastic Syndrome in USD, Million (2015-2025)
Table 22: Japan Market Size of Myelodysplastic Syndrome in USD, Million (2015-2025)


List of Figures

Figure 1: Diagnosed Cases Myelodysplastic Syndrome in United States (2015-2025)
Figure 2: Diagnosed Cases Myelodysplastic Syndrome in Germany (2015-2025)
Figure 3: Diagnosed Cases Myelodysplastic Syndrome in France (2015-2025)
Figure 4: Diagnosed Cases Myelodysplastic Syndrome in United Kingdom (2015-2025)
Figure 5: Diagnosed Cases Myelodysplastic Syndrome in Spain (2015-2025)
Figure 6: Diagnosed Cases Myelodysplastic Syndrome in Italy (2015-2025)
Figure 7: Diagnosed Cases Myelodysplastic Syndrome in Japan (2015-2025)
Figure 8: List of Marketed Drugs for Myelodysplastic Syndrome
Figure 9: List of Pipeline Phase III Drugs for Myelodysplastic Syndrome
Figure 10: Drug 1, Clinical Trials by Zone (%), 2017
Figure 11: Clinical Trials by Trial status, 2017
Figure 12: Drug 2, Clinical Trials by Zone (%), 2017
Figure 13: Clinical Trials by Trial status, 2017
Figure 14: Drug 3, Clinical Trials by Zone (%), 2017
Figure 15: Clinical Trials by Trial status, 2017
Figure 16: United States Market Size of Myelodysplastic Syndrome in USD, Million (2015-2025)
Figure 17: Germany Market Size of Myelodysplastic Syndrome in USD, Million (2015-2025)
Figure 18: France Market Size of Myelodysplastic Syndrome in USD, Million (2015-2025)
Figure 19: United Kingdom Market Size of Myelodysplastic Syndrome in USD, Million (2015-2025)
Figure 20: Spain Market Size of Myelodysplastic Syndrome in USD, Million (2015-2025)
Figure 21: Italy Market Size of Myelodysplastic Syndrome in USD, Million (2015-2025)
Figure 22: Japan Market Size of Myelodysplastic Syndrome in USD, Million (2015-2025)

1 of 3

Type Delivery Format Details
Hard Copy A printed copy of the report will be shipped to you.
CD-ROM The report will be shipped to you in CD ROM format.
SINGLE USER Electronic (PDF) The report will be delivered to your email address in PDF format. The license allows one specific user access to the product.
SITE LICENSE Electronic (PDF) The report will be delivered to your email address in PDF format. The license allows all users within a given geographical location of your organization access to the product.
ENTERPRISEWIDE Electronic (PDF) The report will be delivered to your email address in PDF format. The license allows all employees within your organization in different geographic locations access to the product.
1 - 5 USERS Electronic (PDF) The report will be delivered to your email address in PDF format. The license allows up to five users have access to the product.
1 – 10 USERS Electronic (PDF) The report will be delivered to your email address in PDF format. The license allows up to ten users have access to the product.
1 – 15 USERS Electronic (PDF) The report will be delivered to your email address in PDF format. The license allows up to fifteen users have access to the product.
1 - 5 USERS Online Access (For Databases) Database is accessed online through a secure website. You will receive a username and password via email to access to the online directory. The license allows up to five users have access to the product.
1 - 10 USERS Online Access(For Databases) Database is accessed online through a secure website. You will receive a username and password via email to access to the online directory. The license allows up to ten users have access to the product.
1 - 15 USERS Online Access(For Databases) Database is accessed online through a secure website. You will receive a username and password via email to access to the online directory. The license allows up to fifteen users have access to the product.
1 - 5 USERS Electronic (Excel) The Excel spreadsheet will be emailed to you. The license allows up to five users have access to the product.

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a 1-10 user licence, allowing up to ten users have access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a 1-15 user licence, allowing up to fifteen users have access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a 1-15 user licence, allowing up to fifteen users have access to the product.